Breaking Finance News

A statement released earlier today by Mizuho Securities about Mallinckrodt plc (NYSE:MNK) bumps down the target price to $89.00

Mizuho Securities bumped down the target of Mallinckrodt plc (NYSE:MNK) to $89.00 stating a potential upside of 0.23%.

Boasting a price of $72.47, Mallinckrodt plc (NYSE:MNK) traded 1.74% higher on the day. With the last stock price close up 9.75% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Mallinckrodt plc has recorded a 50-day average of $76.22 and a two hundred day average of $66.03. Volume of trade was down over the average, with 1,389,207 shares of MNK changing hands under the typical 1,624,440

Performance Chart

Mallinckrodt plc (NYSE:MNK)

With a total market value of $0, Mallinckrodt plc has price-earnings ratio of 13.67 with a one year low of $50.90 and a one year high of $85.83 .

A total of 15 equity analysts have released a ratings update on MNK. Six equity analysts rating the company a strong buy, seven equity analysts rating the company a buy, two equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $88.67.

Brief Synopsis About Mallinckrodt plc (NYSE:MNK)

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company's segments include Specialty Brands, Specialty Generics and Nuclear Imaging. Its Specialty Brands segment produces and markets branded pharmaceutical and biopharmaceutical products for autoimmune and rare diseases; immunotherapy and neonatal respiratory critical care therapies, and central nervous system drugs. Its Specialty Generics segment produces specialty generic pharmaceuticals and active pharmaceutical ingredients (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its Nuclear Imaging segment manufactures and markets radiopharmaceuticals (nuclear medicine).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *